Tetrabenazine (Xenazine), An FDA-Approved Treatment Option For Huntington's Disease-Related Chorea

Saved in:
Bibliographic Details
Published inP&T (Lawrenceville, N.J.) Vol. 33; no. 12; pp. 690 - 694
Main Authors Yero, Tatiana, Rey, Jose A
Format Journal Article
LanguageEnglish
Published United States MediMedia USA, Inc 01.12.2008
Subjects
Drug Forecast
tetrabenazine
chorea
Huntington’s disease
Huntington’s chorea
Xenazine
Online AccessGet full text

Cover

More Information
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Dr. Yero is a Psychiatric Pharmacy Practice Resident and Dr. Rey is Associate Professor, both at Nova Southeastern University College of Pharmacy in the Pharmaceutical Sciences Department in Fort Lauderdale, Florida. Drug Forecast is a regular column coordinated by Alan Caspi, PhD, PharmD, MBA, President of Caspi & Associates in New York, New York.
ISSN:1052-1372